Opinion|Videos|May 13, 2025
The Role of Novel Targeted Therapies
Author(s)Kathleen Moore, MD, MS
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Advertisement
Episodes in this series
Video content is prompted by the following:
Novel Targeted Therapies in the Treatment Landscape
Key Themes:
- Emergence of antibody-drug conjugates (ADCs) targeting various receptors
- Movement of ADCs into earlier treatment settings
- Biomarker-directed therapy approach
Notable Insights:
- Multiple ADCs are in development with different targeting mechanisms and payloads:
- Mirvetuximab soravtansine (folate receptor alpha, microtubule toxin)
- Renatabart cecitakin (folate receptor alpha, exatecan payload)
- Trastuzumab deruxtecan (HER2, deruxtecan payload)
- Relutagimod deruxtecan (cadherin-6, deruxtecan payload)
- TORL-1-23 (claudin-6, MMAE payload)
- ADCs are moving from platinum-resistant settings into maintenance therapy and frontline treatment:
- GLORIOSA trial: mirvetuximab plus bevacizumab maintenance after second-line platinum
- Trastuzumab deruxtecan trials in HRD-negative frontline maintenance
- Dr Moore emphasized that these are “very effective medications” but acknowledged: “We’re excited, but there’s a lot we have to learn...there’s just going to be quite a bit of work to do in the next years to really sort this out, to optimize for patients.”
Advertisement
Related to this article
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5